Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma

Archives of Pathology and Laboratory Medicine

Volumn 129, Issue 2, 2005, Pages 194-199

  Croft, Philip R ^a   Lathrop, Sarah L ^a,b   Feddersen, Richard M ^c   Joste, Nancy E ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c Presbyterian Hospital Albuquerque   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA MONOCLONAL ANTIBODY; FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; AGED; BLADDER CARCINOMA; CANCER INVASION; CANCER PATIENT; CELL NUCLEUS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULE; OVARY CARCINOMA; OVARY METASTASIS; PAPILLARY CARCINOMA; PROTEIN EXPRESSION; SEX DIFFERENCE; STATISTICAL ANALYSIS; TISSUE FIXATION; TRANSITIONAL CELL CARCINOMA; TUMOR; UROGENITAL TRACT CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; ESTROGEN RECEPTOR BETA; FEMALE; FORMALDEHYDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; RECEPTORS, ESTROGEN; SEX FACTORS; TISSUE FIXATION; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 13444310789     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol. 1981;141:817-820.
2. Pacchioni D, Revelli A, Casetta G, et al. Immunohistochemical detection of estrogen and progesterone receptors in the normal urinary bladder and in pseudomembranous trigonitis. J Endocrinol Invest. 1992;15:719-725.
3. Saez S, Martin PM. Evidence of estrogen receptors in the trigone area of human urinary bladder. J Steroid Biochem. 1981;15:317-320.
4. Wolf H, Wandt H, Jonat W. Immunohistochemical evidence of estrogen and progesterone receptors in the female lower urinary tract and comparison with the vagina. Gynecol Obstet Invest. 1991;32:227-231.
5. Rizk DE, Raaschou T, Mason N, Berg B. Evidence of progesterone receptors in the mucosa of the urinary bladder. Scand J Urol Nephrol. 2001;35:305-309.
6. Bødker A, Balslev E, Juul BR, et al. Estrogen receptors in the human male bladder, prostatic urethra, and prostate: an immunohistochemical and biochemical study. Scand J Urol Nephrol. 1995;29:161-165.
7. Punnonen R, Lukola A, Puntala P. Lack of estrogen and progestin receptors in the urinary bladder of women. Horm Metabol Res. 1983;15:464-465.
8. Wilson PD, Barker G, Barnard RJ, Siddle NC. Steroid hormone receptors in the female lower urinary tract. Urol Int. 1984;39:5-8.
9. Noronha RF, Rao BR. Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology. 1986;28:401-403.
10. Shan Y, Li L, Yan C, Yin F. Expression of estrogen receptors and progesterone receptors in transitional cell carcinoma of bladder. Chin Med J (Engl). 1998;111:191-192.
11. Kaufmann O, Baume H, Dietel M. Detection of oestrogen receptors in non-invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification(TSA) technique. J Pathol. 1998;186:165-168.
12. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435-1448.
13. Basakci A, Kirkali Z, Tuzel E, Yorukoglu K, Mungan MU, Sade M. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol. 2002;41:342-345.
14. Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S. Effects of sex hormones on development of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Urol Res. 1975;3:73-79.
15. Laor E, Schiffman ZJ, Braunstein JD, et al. Androgen receptors in bladder tumors. Urology. 1985;25:161-163.
16. Pu YS, Hsieh TS, Tsai TC, et al. Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol. 1995;154:601-605.
17. Pu YS, Hsieh TS, Cheng AL, et al. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. Br J Urol. 1996;77:76-85.
18. Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res. 2001;21:711-715.
19. Dellagrammaticas D, Bryden AA, Collins GN. Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol. 2001;165:1631.
20. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol. 2004;28:453-463.
21. Logani S, Oliva E, Amin MB, Folpe AL, Cohen C, Young RH. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers. Am J Surg Pathol. 2003;27:1434-1441.
22. Soslow RA, Rouse RV, Hendrikson MR, Silva EG, Longacre TA. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis. Int J Gynecol Pathol. 1996;15:257-265.